Combinatorial approach of cannabidiol and active‐targeted‐mediated photodynamic therapy in malignant melanoma treatment

Malignant melanoma (MM) continues to claim millions of lives around the world due to its limited therapeutic alternatives. Photodynamic therapy (PDT) has gained popularity in cancer treatment due it increased potency and low off‐target toxicity. Studies have pointed out that the heterogeneity of MM tumours reduces the efficacy of current therapeutic approaches, including PDT, leading to high chances of recurrences post‐treatment. Accumulating evidence suggests that cannabidiol (CBD), a non‐psychoactive derivative of cannabis, can synergise with various anticancer agents to increase their efficacy. However, CBD demonstrates low bioavailability, which is attributed to factors relating to poor water compatibility, poor absorption and rapid metabolism. Nanotechnology offers tools that address these issues and enhance the biological efficiency and targeted specificity of anticancer agents. Herein, we highlighted the standard therapeutic modalities of MM and their pitfalls, as well as pointed out the need for further investigation into PDT combination therapy with CBD. Accumulating evidence suggests that cannabidiol can synergise with various anticancer agents to increase their efficacy although cannabidiol demonstrates low bioavailability. Nanotechnology addresses these issues and enhance the biological efficiency and targeted specificity of anticancer agents such as photodynamic therapy in combination with CBD.